Patents Assigned to Proscan RX Pharma
-
Patent number: 8629247Abstract: Antibodies (Ab) and antigen binding fragments capable of binding to prostate specific membrane antigen and which may be used for diagnostic and therapeutic purposes are provided herein. Formulation anti-PSMA antibodies which are stable under extreme storage condition are also provided.Type: GrantFiled: April 14, 2010Date of Patent: January 14, 2014Assignee: Proscan RX Pharma Inc.Inventors: Serge Moffett, Dominic Melançon, Uri H. Saragovi, Phil Gold, Claudio A. Cuello
-
Patent number: 8512702Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.Type: GrantFiled: December 14, 2011Date of Patent: August 20, 2013Assignee: Proscan Rx Pharma Inc.Inventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Nicole Bernard, Serge Moffett
-
Publication number: 20120093719Abstract: Antibodies (Ab) and antigen binding fragments capable of binding to prostate specific membrane antigen and which may be used for diagnostic and therapeutic purposes are provided herein. Formulation anti-PSMA antibodies which are stable under extreme storage condition are also provided.Type: ApplicationFiled: April 14, 2010Publication date: April 19, 2012Applicant: PROSCAN RX PHARMA INC.Inventors: Serge Moffett, Dominic Melançon, Uri H. Saragovi, Phil Gold, Claudio A. Cuello
-
Publication number: 20120082618Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.Type: ApplicationFiled: December 14, 2011Publication date: April 5, 2012Applicant: PROSCAN RX PHARMA INC.Inventors: CLAUDIO CUELLO, URI SARAGOVI, PIERRE DU RUISSEAU, PHIL GOLD, NICOLE BERNARD, SERGE MOFFETT
-
Patent number: 8101713Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.Type: GrantFiled: September 10, 2010Date of Patent: January 24, 2012Assignee: Proscan RX Pharma Inc.Inventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Nicole Bernard, Serge Moffett
-
Publication number: 20110189093Abstract: Polypeptides, antibodies or antigen-binding fragments capable of binding to prostate specific membrane antigen (PSMA) are provided. These polypeptides, antibodies or antigen-binding fragments may be used for diagnostic and/or therapeutic purposes.Type: ApplicationFiled: April 14, 2009Publication date: August 4, 2011Applicant: PROSCAN RX PHARMAInventors: Serge Moffett, Dominic Melancon, Uri H. Saragovi, Phil Gold, Claudio A. Cuello
-
Patent number: 7910693Abstract: The present invention relates to novel mimetopes of anti-PSMA antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastatis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.Type: GrantFiled: April 19, 2005Date of Patent: March 22, 2011Assignee: ProScan Rx Pharma Inc.Inventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Serge Moffett
-
Publication number: 20110064654Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.Type: ApplicationFiled: September 10, 2010Publication date: March 17, 2011Applicant: Proscan Rx Pharma Inc.Inventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Nicole Bernard, Serge Moffett
-
Patent number: 7811564Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.Type: GrantFiled: January 28, 2004Date of Patent: October 12, 2010Assignee: Proscan RX PharmaInventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Nicole Bernard, Serge Moffet
-
Publication number: 20090131277Abstract: The present invention relates to novel mimetopes of anti-PSMA antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastatis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.Type: ApplicationFiled: April 19, 2005Publication date: May 21, 2009Applicant: PROSCAN RX PHARMAInventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Serge Moffett